Citations

Clear

25 citation(s) found for "Thomas, Matthew".

Abstract 1860: DNA-PK-mediated transcriptional regulation drives tumor progression and metastasis
Goodwin, Jonathan F., Zhao, Shuang , Dylgjeri, Emanuela , Dean, Jeffry L. , Graham, Nicholas , Vashisht, Ajay A., Karnes, R. Jeffrey , Takhar, Mandeep, Tomlins, Scott A. , Sharifi, Nima , Witte, Owen N. , Feng, Felix Y. , Kothari, Vishal , Drake, Justin M , Schiewer, Matthew J. , McNair, Christopher M. , Magee, Michael S. , Den, Robert B. , Zhu, Ziqi , Wohlschlegel, James Akira , Graeber, Thomas G. , Davicioni, Elai , Knudsen, Karen E.

Mayo Clinic

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 1860-1860

10.1158/1538-7445.am2015-1860 Get It

Abstract Emerging evidence demonstrates that the DNA repair kinase DNA-PK exerts divergent roles in transcriptional regulation of unsolved consequence. Here, in vitro and in vivo interrogation demonstrate that DNA-PK functions as a selective modulator of transcriptional networks that induce cell migration, invasion, and metastasis. Accordingly, suppression of DNA-PK inhibits tumor metastases. Clinical assessment revealed that DNA-PK is significantly elevated in advanced disease, and independently predicts for metastases, recurrence, and reduced overall survival. Further investigation demonstrated that DNA-PK in advanced tumors is highly activated, independently of DNA damage indicators. Combined, these findings put forth new paradigms for DNA-PK function, identify DNA-PK as a potent driver of tumor progression and metastases, and nominate DNA-PK as a therapeutic target for advanced malignancies. Citation Format: Jonathan F. Goodwin, Vishal Kothari, Justin M. Drake, Shuang Zhao, Emanuela Dylgjeri, Jeffry L. Dean, Matthew J. Schiewer, Christopher McNair, Michael S. Magee, Robert B. Den, Ziqi Zhu, Nicholas A. Graham, Ajay A. Vashisht, James A. Wohlschlegel, Thomas G. Graeber, R Jeffrey Karnes, Mandeep Takhar, Elai Davicioni, Scott A. Tomlins, Nima Sharifi, Owen N. Witte, Felix Y. Feng, Karen E. Knudsen. DNA-PK-mediated transcriptional regulation drives tumor progression and metastasis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1860. doi:10.1158/1538-7445.AM2015-1860
Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma
Thompson, Carrie A. , Ghesquières, Hervé , Maurer, Matthew J. , Biron, Pierre, Ansell, Stephen M. , Chassagne‐Clément, Catherine, Inwards, David J. , Gargi, Thérèse, Johnston, Patrick B. , Nicolas‐Virelizier, Emmanuelle , Macon, William R. , Peix, Marie, Micallef, Ivana N. , Sebban, Catherine, Nowakowski, Grzegorz S. , Porrata, Luis F. , Weiner, George J. , Link, Brian K. , Chassagne-Clément, Catherine, Nicolas-Virelizier, Emmanuelle, Cerhan, James R. , Witzig, Thomas E. , Habermann, Thomas M. , Maurer, Matthew , Link, Brian K , Weiner, George

Mayo Clinic

Journal of Clinical Oncology | September 30, 2014 | Volume: 32 | Issue: 31 | Pages: 3506-3512

10.1200/jco.2014.55.7561 | PMID 25267745 Get It

Purpose We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuse large B-cell lymphoma (DLBCL) from the United States and confirmed our results in an independent cohort of patients from France. Methods Patients with newly diagnosed DLBCL and treated with anthracycline-based immunochemotherapy were identified from the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence and the Léon Bérard Cancer Center, Lyon, France. In those with relapse, details at relapse and outcomes were abstracted from records. Results 680 individuals with DLBCL were identified from the MER, 552 (81%) of whom achieved remission after induction. 112 of the 552 patients (20%) suffered a relapse. The majority (64%) of relapses were identified before a scheduled follow-up visit. Surveillance imaging detected DLBCL relapse before clinical manifestations in nine out of 552 patients (1.6%) observed after therapy. In the Lyon cohort, imaging identified asymptomatic DLBCL relapse in four out of 222 patients (1.8%). There was no difference in survival after DLBCL relapse in patients detected at scheduled follow-up versus before scheduled follow-up in both the MER (P = .56) and Lyon cohorts (P = .25). Conclusion The majority of DLBCL relapses are detected outside of planned follow-up, with no difference in outcome in patients with DLBCL detected at a scheduled visit compared with patients with relapse detected outside of planned follow-up. These data do not support the use of routine surveillance imaging for follow-up of DLBCL.
Improved Resident Physician Confidence With Advance Care Planning After an Ambulatory Clinic Intervention
Tung, Ericka E. , Verdoorn, Brandon P. , Mauck, Karen F. , Post, Jason , Thomas, Matthew R. , Bundrick, John B., Jaeger, Thomas M. , Cha, Stephen S., Thomas, Kris G., Wieland, Mark L. , Cha, Stephen S.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | April 15, 2013 | Volume: 31 | Issue: 3 | Pages: 275-280

10.1177/1049909113485636 | PMID 23588577 Get It

Many primary care providers feel uncomfortable discussing end-of-life care. The aim of this intervention was to assess internal medicine residents’ advance care planning (ACP) practices and improve residents’ ACP confidence. Residents participated in a facilitated ACP quality improvement workshop, which included an interactive presentation and chart audit of their own patients. Pre- and postintervention surveys assessed resident ACP-related confidence. Only 24% of the audited patients had an advance directive (AD), and 28% of the ACP-documentation was of no clinical utility. Terminally ill patients (odds ratio 2.8, P < .001) were more likely to have an AD. Patients requiring an interpreter were less likely to have participated in ACP. Residents reported significantly improved confidence with ACP and identified important training gaps. Future studies examining the impact on ACP quality are needed.
Burnout and Suicidal Ideation among U.S. Medical Students
Thomas, Matthew R. , Massie, F. Stanford, Power, David V. , Eacker, Anne, Harper, William R., Durning, Steven J. , Moutier, Christine , Szydlo, Daniel , Novotny, Paul J. , Sloan, Jeff A. , Dyrbye, Liselotte N. , Shanafelt, Tait D.

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 149 | Issue: 5 | Pages: 334-341

10.7326/0003-4819-149-5-200809020-00008 | PMID 18765703 Get It

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
Lee, Stephanie J. , Kukreja, Manisha, Szer, Jeff , Arora, Mukta , Woolfrey, Ann E. , Cervantes, Francisco , Halter, Joerg , Marks, David I. , Olavarría, Eduardo, Stadtmauer, Edward A. , Abecasis, Manuel, Gupta, Vikas , Khoury, H. Jean, Hale, Gregory A., Rizzieri, David A. , Antin, Joseph H. , Bolwell, Brian J., Carabasi, Matthew, Copelan, Edward A. , İlhan, Osman , Litzow, Mark R. , Schouten, H, Zander, Axel R., Horowitz, Mary M. , Halter, Jörg , Wang, Tao , Giralt, Sergio , Champlin, Richard E. , Gale, Robert Peter , Keating, Armand , McCarthy, Philip L. , George, Biju , Liesveld, Jane L. , Maziarz, Richard Thomas , Gupta, Vikas , Lee, Stephanie J

Mayo Clinic

Blood | July 30, 2008 | Volume: 112 | Issue: 8 | Pages: 3500-3507

10.1182/blood-2008-02-141689 | PMID 18664621 Get It

AbstractImatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data from the Center for International Blood and Marrow Transplant Research on 409 subjects treated with IM before HCT (IM+) and 900 subjects who did not receive IM before HCT (IM−) were analyzed. Among patients in first chronic phase, IM therapy before HCT was associated with better survival but no statistically significant differences in treatment-related mortality, relapse, and leukemia-free survival. Better HLA-matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival. A matched-pairs analysis was performed and confirmed a higher survival rate among first chronic phase patients receiving IM. Among patients transplanted with advanced CML, use of IM before HCT was not associated with treatment-related mortality, relapse, leukemia-free survival, or survival. Acute graft-versus-host disease rates were similar between IM+ and IM− groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT.